Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel interacting protein 2 (KCNIP2)
- Target
- KCNIP2
- Molecular classification
- Ion channel regulatory subunit, Calcium-binding protein, Voltage-gated potassium (Kv) channel-interacting protein
01
Overview
Potassium voltage-gated channel interacting protein 2 (KCNIP2) is a small calcium-binding protein that acts as a crucial regulatory subunit for Kv4/D-type rapidly inactivating (A-type) potassium channels in neurons and cardiac cells, primarily by influencing channel density, inactivation, and recovery kinetics in a calcium-dependent manner[1][3][5][8]. KCNIP2 is highly expressed in both brain and heart tissue and plays a central role in neuronal excitability and cardiac repolarization, with altered expression or function being implicated in diseases such as Brugada syndrome, cardiac arrhythmias, and some neurodegenerative disorders[1][2][3].
- Other names
- KChIP2Kv channel-interacting protein 2A-type potassium channel modulatory protein 2Cardiac voltage-gated potassium channel modulatory subunitPotassium channel-interacting protein 2KCHIP2
02
Mechanism of action
Modulation of Kv4/D (Shal)-type rapidly inactivating A-type potassium channel gating in a calcium-dependent fashion; Regulation of membrane trafficking of specific cardiac and neuronal Kv channels (e.g., KCND2 and KCND3)[3][5][8]
03
Biological functions
Regulation of A-type potassium channel current (I_to)Modulation of channel density, inactivation kinetics, and recovery from inactivation (calcium-dependent and isoform-specific)Regulation of neuronal excitabilityRegulation of cardiac action potential and repolarization
04
Disease associations
Cardiovascular disease (notably cardiac arrhythmias such as Brugada syndrome)Neurodegenerative disease (e.g., spinocerebellar ataxia type 19/22)
05
Safety considerations
Potential proarrhythmic effects resulting from the inhibition or genetic ablation of KCNIP2, particularly heightened risk of cardiac arrhythmias and sudden cardiac death[2][3]
06
Biomarkers
Abnormal KCNIP2 expression may serve as a biomarker in cardiac electrophysiological disorders (e.g., Brugada syndrome)[3]
Beyond the preview
Go deeper on Potassium voltage-gated channel interacting protein 2 (KCNIP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium voltage-gated channel interacting protein 2 (KCNIP2).